ClinicalTrials.gg
RecruitingNCT06200220Updated Jan 10, 2024

Patients Treated in Real Life With VEnetoclax for WAldenström Macroglobulinemia

An observational study in Waldenstrom's Macroglobulinaemia Refractory, sponsored by Poitiers University Hospital. Recruiting at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-01-10.

Sponsored by Poitiers University Hospital · Observational

How we know

From the registry’s dates

  • Started Dec 2023; still recruiting 2 years 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
45
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Waldenstrom Macroglobulinemia with a site in France — 11 open to participants now, 16 under way, 1 of them phase 3. Waldenstrom Macroglobulinemia · France.

Started
2023
with 3 others
Observational
5 of 41
2 open now
Primary completion
2023-12
later than 1 of 15 live
Registered
38th of 41
by date

Among the 41 studies in Waldenstrom Macroglobulinemia with a site in France, this one is one of 4 that started in 2023, is one of 5 observational ones, reaches primary completion later than 1 of the 15 other live ones, and was the 38th registered.

Waldenstrom Macroglobulinemia

524 studies on the registry are indexed under Waldenstrom Macroglobulinemia; 61 are open to participants now.

Browse Waldenstrom Macroglobulinemia studies →

Open to participants now

11 of the 41 studies in Waldenstrom Macroglobulinemia with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 47 Waldenstrom Macroglobulinemia studies recruiting now, 43 (91%) set no upper age limit and 1 (2%) stops at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Waldenstrom Macroglobulinemia with a site in France, or all of them as a file.
02

Study summary

Waldenström macroglobulinemia (WM) is an incurable disease. BCL2 antagonist, an important anti-apoptosys molecule, is already approved for the treatment of chronic lymphocytic leukemia (CLL) and acute myeloid leukemia. Recently, a clinical trial including 32 patients with WM treated with Venetoclax showed an overall response rates of 84% and a major response rate of 81%. However, there is no in real life data, in the french population, of the efficiency of Venetoclax in WM. The aim of our multicentric retrospective study is to evaluate the efficiency and tolerance of Venetoclax in WM.

03

Conditions studied

  • Waldenstrom's Macroglobulinaemia Refractory
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Patients from university hospitals in France (16 center)

Eligibility criteria

Inclusion Criteria:

  • Waldenstrom's macroglobulinemia
  • Treatment with Venetoclax
  • Non opposition

Exclusion Criteria: none

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
45 participants (estimated)
Patient registry
No

Interventions

06

What researchers measure

Primary outcomes

  1. Efficiency

    ORR, MRR

    Time frame: 2018 to 2025

Secondary outcomes

  1. Tolerance

    Adverse events

    Time frame: 2018 to 2025

  2. Efficiency in specific population

    ORR in CXCR4 mutated patients, ORR in patients previously treated with BTK inhibitors

    Time frame: 2018 to 2025

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2023 to primary completion in Dec 2023, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 28, 2023
First posted
Jan 10, 2024
StartActual
Dec 28, 2023
Primary completionActual
Dec 28, 2023
CompletionEst.
Dec 1, 2025
Last update
Jan 10, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06200220
Responsible party
Sponsor
First posted
Jan 10, 2024
Start date
Dec 28, 2023
Primary completion
Dec 28, 2023
Completion
Dec 1, 2025 (estimated)
Last update
Jan 10, 2024

Study contacts

cécile tomowiak, Dr
Contact
cecile.tomowiak@chu-poitiers.fr
+33 (0)5.49.44.43.07
Mathilde Vonfeld, Intern
Contact
mathilde.vonfeld@chu-poitiers.fr
+33 (0)5.49.44.43.07

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion